CompletedPhase 3NCT04541043

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Calliditas Therapeutics AB
Principal Investigator: Richard Philipson, MD, M.D
Calliditas Therapeutics AB
Intervention: Nefecon 16mg daily(drug)
Enrollment: 119 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2024

Study locations (18)

13 Investigator sites, Palo Alto, California, United States
4 Investigator sites, Buenos Aires, Argentina
6 Investigator sites, Melbourne, Australia
3 Investigator sites, Minsk, Belarus
4 Investigator sites, Brussels, Belgium
7 Investigator sites, Québec, Canada
6 Investigator sites, Prague, Czechia
2 Investigator sites, Jyväskylä, Finland
2 Investigator sites, Saint-Priest-en-Jarez, France
5 Investigator sites, Aachen, Germany
5 Investigator sites, Athens, Greece
2 Investigator sites, Milan, Italy
2 Investigator sites, Lodz, Poland
4 Investigator sites, Gyeonggi-do, South Korea
4 Investigator sites, Barcelona, Spain
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04541043 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials